monalizumab monalizumab monalizumab (formerly iph2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies and other cancers. monalizumabmonoclonal antibodytype?sourcehumanizedtargetnkg2alegal statuslegal status investigational identifierscas number1228763-95-8chemspidernoneunii3zxz2v0588 mechanism of action monalizumab is a monoclonal antibody targeted at nkg2a. it is a checkpoint inhibitor.